The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.
Also called NCT02281838
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 142 participants
- Sponsor
- Registry
-
NCT02281838
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Terminated
Technical summary
Registry record NCT02281838. Randomized; no masking; primary purpose treatment. Start 2011-08-01 (actual); primary completion 2021-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II
- Acronym
- ICH-ADAPT II
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- labetalol/hydralazine/enalapril
- Lead sponsor
- University of Alberta
Record details
- Record id
cardio:ct-nct02281838- Content hash
b46f118378a3cc420b0cfc138706a00d241608b44e0b775e01b202248362dac8